Alerta

ＲＮＡアジュバント、その方法及び使用

Absstract of: US2025161438A1

Provided herein are adjuvants, compositions, and methods for the prevention and treatment of infectious diseases and cancer. Various toll-like receptor (TLR) agonists and RNA encoding TLR agonists are provided herein. The adjuvants provided herein can be complexed with a carrier or formulated with a delivery vehicle for administration to a subject. Further provided are adjuvants that can be delivered with vaccine compositions or as part of a vaccine composition to enhance the innate immune response in a subject.

タンパク質とバイオポリマーとの複合体、並びにその製造方法及び使用方法

Absstract of: MX2024014053A

Described herein are complexes including a protein, an anionic biopolymer, and a cationic biopolymer along with methods of making and using such complexes. The complex may include lactoferrin, gelatin, and a polysaccharide.

脂質粒子、脂質粒子を含む組成物、脂質粒子を含むキット、および脂質粒子を利用した活性剤送達方法

Absstract of: US2025195430A1

Provided are a lipid particle with high biodegradability, high biocompatibility, a high active agent introducibility, low cytotoxicity, and the like, a composition and a kit which use the lipid particle, and a method of delivering an active agent to a cell.The lipid particle according to the present embodiment comprises:a compound represented by the following Formula (a),Mal-La1-(OCH2CH2)na—O-La2Ra2  (a)(in the formula,Mal is a maleimide group,La1 is an unsubstituted hydrocarbon group, or a substituted hydrocarbon group,La2 is a trivalent hydrocarbon group that does not contain phosphorus,Ra's are a hydrocarbon group containing at least one ester bond at a predetermined position, andna is a number of 1 or more); andan active agent.

ＳＡＲＳ－ＣＯＶ－２免疫原性組成物

Absstract of: WO2025106738A1

Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can result in an improved immune response as compared to current SARS-COV-2 vaccines.

一种载亚硝基血红蛋白的膜融合仿生纳米载体、其制备方法和应用

Absstract of: CN120227356A

本发明公开了一种载亚硝基血红蛋白的膜融合仿生纳米载体、其制备方法和应用；所述膜融合仿生纳米载体，其膜壳由合成磷脂与血小板膜杂化融合而成，膜壳内包封有亚硝基血红蛋白的水溶液，所述亚硝基血红蛋白是由血红蛋白经脱氧处理后，与一氧化氮分子反应制备而成；所述膜融合仿生纳米载体具有良好的生物相容性和天然靶向性，可以快速、高效地靶向心脑血管疾病病灶，所递送的亚硝基血红蛋白不仅保留了一氧化氮气体分子的血管扩张等生物活性，同时具有顺磁性，可有效增强磁共振显影效果，可作为载体为一氧化氮分子在缺血性心脑血管疾病病灶的有效递送和磁共振影像诊断提供了新工具。

一种可电离阳离子脂质化合物及其应用

Absstract of: CN120230169A

本发明提供了一种具有式(I)所示结构的可电离阳离子脂质化合物，其可用于制备用于递送治疗剂和/或预防剂的脂质纳米颗粒(LNP)。利用本发明的可电离阳离子脂质化合物制备的LNP具有较佳的稳定性和转染效率，可以高效地、稳定地将生物活性物质(包括核酸，例如mRNA)递送至靶细胞或器官，从而在体内引起高特异性抗体应答。#imgabs0#

Devices and methods for extracorporeal cell treatment

Absstract of: AU2023374051A1

The present disclosure features a method of preparing a population of payload-associated cell complexes (PACCs), as well as related methods of use thereof.

Synthetic single-stranded dna molecules and methods of producing and using the same

Absstract of: AU2023406947A1

The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.

Formulations

Absstract of: MX2024013597A

The invention provides lipid nanoparticle-based compositions with improved properties for delivery of biologically active agents, engineered cells, and methods for delivery of the agents.

Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses

Absstract of: AU2023406303A1

Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA), wherein the LNP comprises an ionizable lipid; a "helper" lipid, e.g., a ceramide or distearoylphosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, as well as uses thereof.

Synthetic single stranded nucleic acid compositions and methods thereof

Absstract of: AU2023406947A1

The present application discloses modified single-stranded DNA molecules, as well as their cell-free methods of synthesis and their use as therapeutic agents.

Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same

Absstract of: AU2023406321A1

The present disclosure provides novel polymer-conjugated lipids, e.g., comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations.

Antiviral prodrugs and nanoformulations thereof

Absstract of: US2025099477A1

The present invention provides prodrugs and methods of use thereof.

Stealth lipid nanoparticle compositions for cell targeting

Absstract of: AU2023406483A1

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types,

Use of nano-carriers for delivery of active agents

Absstract of: WO2024110835A1

There are disclosed uses of compositions for the preparation of medications for the treatment of a subject or an object in need thereof, the compositions comprising nano-elements containing: a) at least one water-insoluble thermoplastic compound (WITC), capable of forming a core; and b) at least one active agent which can be disposed in said core or in shells surrounding the core. The nano-elements, having an average diameter in the sub-micron range, are constituted of materials having a low vapor pressure and are dispersible in a polar carrier. Methods for preparing these nano-elements, and administering them, so as to treat conditions corresponding to the active agents contained therein, are also provided.

Lipid nanoparticle compositions and uses thereof

Absstract of: AU2023391361A1

Provided are aerosolized pharmaceutical compositions including aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are liquid pharmaceutical compositions for use in making aerosolized pharmaceutical compositions. Also provided herein are methods of administering the aerosolized pharmaceutical compositions. Also provided herein are kits including a lipid nanoparticle composition including one or more of a phospholipid, an ionizable lipid, a PEG-lipid, a sterol.

一种诱发细胞焦亡的纳米转换器及其制备方法与应用

Absstract of: CN120227459A

本发明公开了一种诱发细胞焦亡的纳米转换器及其制备方法与应用。所述纳米转换器的制备原料包括能量供体、光敏剂、胆固醇氧化酶和马来酰亚胺‑1，2‑二硬脂酰基‑sn‑甘油‑3‑磷酸乙醇胺‑聚(乙二醇)(Mal‑DSPE‑PEG)。所述纳米转换器中双草酸酯与二氢卟吩e6通过亲疏水相互作用与Mal‑DSPE‑PEG形成纳米胶束，胆固醇氧化酶通过和马来酰亚胺反应而被修饰在纳米胶束的表面。所述纳米转换器可以有效的将肿瘤衰老细胞中的胆固醇和过氧化氢转换为单线态氧最终导致肿瘤衰老细胞的焦亡。本发明公开的纳米转换器由于靶向了肿瘤衰老细胞普遍存在的代谢特征而具有普适性和高的安全性。此外该纳米转换器利用化学能驱动光动力学治疗，由于不依赖外在光源而降低了可能存在的光毒性。

Naringin nanoparticle and composition for cranial nerve protection comprising the same

Absstract of: KR20250097322A

본 발명은 (a) 나린진 수용액과 키토산 수용액을 혼합하여 나린진-키토산 혼합용액을 제조하는 단계; (b) 상기 나린진-키토산 혼합용액을 초음파 처리하면서 적가(dropwise)하여 나린진-키토산 나노파티클을 형성하는 단계; (c) 상기 나린진-키토산 나노파티클이 형성된 혼합용액을 교반시키는 단계; (d) 상기 교반된 나린진-키토산 나노파티클이 형성된 혼합용액에 가용화제를 첨가하여 나린진-키토산-가용화제 혼합용액을 제조하는 단계; 및 (e) 상기 나린진-키토산-가용화제 혼합용액을 초음파 처리하면서 적가(dropwise)하여 나린진이 내포된 캡슐형 나노파티클을 제조하는 단계;를 포함하는 나린진 나노파티클의 제조방법 에 관한 것이다. 이에 의하여, 본 발명의 항염 또는 면역 증진용 조성물은 염증을 개선하며 NF-TIFFpat00002.tif63B 신호전달경로의 활성화에 의한 면역 증진 효과를 나타낼 수 있다. 이에 의하여, 본 발명의 제조방법에 따라 제조된 나린진 나노파티클은 무처리된 종래 나린진에 비해 물에 대한 용해도가 높고, 체내 흡수율이 높으며, 쓴맛이 저감되고, 뇌세포보호능이 현저히 높아져 식품, 의약 등에 활용하기에 유리하다.

PEGylated hydroxyapatite zirconium oxide nanoparticles and method for producing the same

Absstract of: KR20250097356A

본 발명은 수산화인회석 산화지르코늄 나노입자를 합성하고, 이를 페길화하여 생물학적으로 응용할 수 있도록 한 페길화된 수산화인회석 산화지르코늄 나노입자 및 그 제조방법에 관한 것이다.

- Paeonia lactiflora Pall extract conjugated silver-nitrophurside nanoparticles and method for producing the same

Nº publicación: KR20250097357A 30/06/2025

Applicant:

강원대학교산학협력단